Inflammation and the development of atherosclerosis - Effects of lipid-lowering therapy

Journal of Atherosclerosis and Thrombosis

Volumn 18, Issue 5, 2011, Pages 351-358

  Mizuno, Yoshiko ^a   Jacob, Robert Francis ^b   Preston Mason, R ^b,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b ELUCIDA RESEARCH LLC   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Endothelial function; Inflammation; Oxidized lipids; Statins

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; DRUG EFFECT; DRUG EFFICACY; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; OXIDATIVE STRESS; REVIEW; VASCULAR ENDOTHELIUM;

ANIMALS; ATHEROSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION;

EID: 79958032424     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.7591     Document Type: Review

References (82)

1. Fuster V, Fayad ZA, Badimon JJ: Acute coronary syndromes: biology. Lancet, 1999; 353 Suppl 2: SE5-SII9
2. Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med, 1999; 340: 115-126
3. Fuster V, Badimon L, Badimon JJ, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med, 1992; 326: 310-318
4. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ: Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med, 1987; 316: 1371-1375
5. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT: Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation, 1994; 90: 775-778
6. Falk E, Shah PK, Fuster V: Coronary plaque disruption. Circulation, 1995; 92: 657-671
7. Libby P: Current concepts of the pathogenesis of the acute coronary syndromes. Circulation, 2001; 104: 365-372
8. Libby P: Inflammation in atherosclerosis. Nature, 2002; 420: 868-874
9. Moore KJ, Freeman MW: Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol, 2006; 26: 1702-1711
10. van Berkel TJ, Out R, Hoekstra M, Kuiper J, Biessen E, van Eck M: Scavenger receptors: friend or foe in atherosclerosis? Curr Opin Lipidol, 2005; 16: 525-535
11. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J: Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J, 1993; 69: 377-381
12. Deguchi JO, Aikawa M, Tung CH, Aikawa E, Kim DE, Ntziachristos V, Weissleder R, Libby P: Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation, 2006; 114: 55-62
13. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mail-hac A, Villareal-Levy G, Fallon JT, Regnstrom J, Fuster V: Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation, 1995; 92: 1565-1569
14. Satoh M, Shimoda Y, Akatsu T, Ishikawa Y, Minami Y, Nakamura M: Elevated circulating levels of heat shock protein 70 are related to systemic inflammatory reaction through monocyte Toll signal in patients with heart failure after acute myocardial infarction. Eur J Heart Fail, 2006; 8: 810-815
15. Methe H, Kim JO, Kofler S, Weis M, Nabauer M, Koglin J: Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation, 2005; 111: 2654-2661
16. Ray KK, Morrow DA, Sabatine MS, Shui A, Rifai N, Cannon C P, Braunwald E: Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation, 2007; 115: 3071-3078
17. Cheng GC, Loree HM, Kamm RD, Fishbein MC, Lee RT: Distribution of circumferential stress in ruptured and stable atherosclerotic lesions. A structural analysis with histopathological correlation. Circulation, 1993; 87: 1179-1187
18. Davies MJ: Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation, 1996; 94: 2013-2020
19. Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest, 1994; 94: 2493-2503
20. Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, Humphries S: Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A, 1991; 88: 8154-8158
21. Libby P, Aikawa M: Evolution and stabilization of vulnerable atherosclerotic plaques. Jpn Circ J, 2001; 65: 473-479
22. Nikkari ST, O'Brien KD, Ferguson M, Hatsukami T, Welgus HG, Alpers CE, Clowes AW: Interstitial collage-nase (MMP-1) expression in human carotid atherosclerosis. Circulation, 1995; 92: 1393-1398
23. Sukhova GK, Schonbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, Libby P: Evidence for increased col-lagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation, 1999; 99: 2503-2509
24. Naruko T, Ueda M, Haze K, van der Wal AC, van der Loos CM, Itoh A, Komatsu R, Ikura Y, Ogami M, Shi-mada Y, Ehara S, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE: Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation, 2002; 106: 2894-2900
25. van der Wal AC, Becker AE, van der Loos CM, Das PK: Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation, 1994; 89: 36-44
26. Clarke MC, Figg N, Maguire JJ, Davenport A P, Goddard M, Littlewood TD, Bennett MR: Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med, 2006; 12: 1075-1080
27. Stary HC: Composition and classification of human atherosclerotic lesions. Virchows Arch A Pathol Anat Histo-pathol, 1992; 421: 277-290
28. Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH: Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med, 2001; 134: 224-238
29. Nemerson Y: Tissue factor and hemostasis. Blood, 1988; 71: 1-8
30. Mallat Z, Tedgui A: Current perspective on the role of apoptosis in atherothrombotic disease. Circ Res, 2001; 88: 998-1003
31. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ: Tissue factor modulates the throm-bogenicity of human atherosclerotic plaques. Circulation, 1997; 95: 594-599
32. Meyer BJ, Badimon JJ, Mailhac A, Fernandez-Ortiz A, Chesebro JH, Fuster V, Badimon L: Inhibition of growth of thrombus on fresh mural thrombus. Targeting optimal therapy. Circulation, 1994; 90: 2432-2438
33. Kaikita K, Ogawa H, Yasue H, Takeya M, Takahashi K, Saito T, Hayasaki K, Horiuchi K, Takizawa A, Kamikubo Y, Nakamura S: Tissue factor expression on macrophages in coronary plaques in patients with unstable angina. Ar-terioscler Thromb Vasc Biol, 1997; 17: 2232-2237
34. Soejima H, Ogawa H, Yasue H, Kaikita K, Nishiyama K, Misumi K, Takazoe K, Miyao Y, Yoshimura M, Kugiyama K, Nakamura S, Tsuji I, Kumeda K: Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation, 1999; 99: 2908-2913
35. Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, Badimon L: Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation, 1999; 99: 1780-1787
36. Corti R, Fuster V, Badimon JJ: Pathogenetic concepts of acute coronary syndromes. J Am Coll Cardiol, 2003; 41: 7S-14S
37. Tan KC, Chow WS, Ai VH, Metz C, Bucala R, Lam KS: Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care, 2002; 25: 1055-1059
38. Davignon J, Ganz P: Role of endothelial dysfunction in atherosclerosis. Circulation, 2004; 109: III27-III32
39. Ruschitzka F, Moehrlen U, Quaschning T, Lachat M, Noll G, Shaw S, Yang Z, Teupser D, Subkowski T, Turina MI, Luscher TF: Tissue endothelin-converting enzyme activity correlates with cardiovascular risk factors in coronary artery disease. Circulation, 2000; 102: 1086-1092
40. Kinlay S, Libby P, Ganz P: Endothelial function and coronary artery disease. Curr Opin Lipidol, 2001; 12: 383-389
41. Moore KL, Andreoli S P, Esmon NL, Esmon CT, Bang NU: Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothe-lium in vitro. J Clin Invest, 1987; 79: 124-130
42. Rajavashisth TB, Liao JK, Galis ZS, Tripathi S, Laufs U, Tripathi J, Chai NN, Xu X P, Jovinge S, Shah PK, Libby P: Inflammatory cytokines and oxidized low density lipopro-teins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem, 1999; 274: 11924-11929
43. De Caterina R, Libby P, Peng HB, Thannickal VJ, Raja-vashisth TB, Gimbrone MA, Jr., Shin WS, Liao JK: Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest, 1995; 96: 60-68
44. Thurberg BL, Collins T: The nuclear factor-kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis. Curr Opin Lipidol, 1998; 9: 387-396
45. Peng HB, Libby P, Liao JK: Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem, 1995; 270: 14214-14219
46. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, Komatsu R, Matsuo T, Itabe H, Takano T, Tsukamoto Y, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE: Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation, 2001; 103: 1955
47. Walter M F, Jacob R F, Bjork RE, Jeffers B, Buch J, Mizu-no Y, Mason RP: Circulating lipid hydroperoxides predict cardiovascular events in patients with stable coronary artery disease: the PREVENT study. J Am Coll Cardiol, 2008; 51: 1196-1202
48. Walter MF, Jacob RF, Jeffers B, Ghadanfar MM, Preston GM, Buch J, Mason RP: Serum levels of TBARS predict cardiovascular events in patients with stable coronary artery disease: A longitudinal analysis of the PREVENT study. J Am Coll Cardiol, 2004; 44: 1996-2002
49. Ganné F, Vasse M, Beaudeux JL, Peynet J, François A, Mishal Z, Chartier A, Tobelem G, Vannier J P, Soria J, So-ria C: Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes--a possible protective mechanism against atherothrombosis. Thrombosis and haemostasis, 2000; 84: 680-688
50. Ganné F, Vasse M, Beaudeux JL, Peynet J, François A, Paysant J, Lenormand B, Collet J P, Vannier J P, Soria J, Soria C: Increased expression of u-PA and u-PAR on monocytes by LDL and Lp(a) lipoproteins--consequences for plasmin generation and monocyte adhesion. Thrombosis and haemostasis, 1999; 81: 594-600
51. Ishigaki Y, Oka Y, Katagiri H: Circulating oxidized LDL: a biomarker and a pathogenic factor. Curr Opin Lipidol, 2009; 20: 363-369
52. Jain MK, Ridker PM: Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov, 2005; 4: 977-987
53. Schonbeck U, Libby P: Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation, 2004; 109: II18-1126
54. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goor-mastic M, Tuzcu EM: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA, 2006; 295: 1556-1565
55. Nissen SE, Tuzcu EM, Schoenhagen P, REVERSAL-In-vestigators F: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. JAMA, 2004; 291: 1071-1080
56. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJP, Stalenhoef AFH: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial. Lancet, 2001; 357: 577-581
57. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008; 359: 2195-2207
58. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med, 2008; 358: 1431-1443
59. Mason RP, Walter MF, Day CA, Jacob RF: Intermolecular differences for HMG-CoA reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol, 2005; 96[Suppl]: 11F-23F
60. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hen-nekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med, 1997; 336: 973-979
61. Ridker PM, Glynn RJ, Hennekens CH: C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation, 1998; 97: 2007-2011
62. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med, 2000; 342: 836-843
63. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P: Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med, 2005; 352: 29-38
64. Aikawa M, Rabkin E, Okada Y, Voglic SJ, Clinton SK, Brinckerhoff CE, Sukhova GK, Libby P: Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation, 1998; 97: 2433-2444
65. Bustos C, Hernandez-Presa MA, Ortego M, Tunon J, Ortega L, Perez F, Diaz C, Hernandez G, Egido J: HMG-CoA reductase inhibition by atorvastatin reduces neointi-mal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol, 1998; 32: 2057-2064
66. Aikawa M, Voglic SJ, Sugiyama S, Rabkin E, Taubman MB, Fallon JT, Libby P: Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation, 1999; 100: 1215-1222
67. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, Shiomi M, Schoen FJ, Libby P: An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation, 2001; 103: 276-283
68. Aikawa M, Sugiyama S, Hill CC, Voglic SJ, Rabkin E, Fukumoto Y, Schoen FJ, Witztum JL, Libby P: Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation, 2002; 106: 1390-1396
69. Mason R P, Walter M F, Day CA, Jacob RF: Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. J Biol Chem, 2006; 281: 9337-9345
70. Rauch U, Osende JI, Chesebro JH, Fuster V, Vorchheimer DA, Harris K, Harris P, Sandler DA, Fallon JT, Jayaraman S, Badimon JJ: Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins. Atherosclerosis, 2000; 153: 181-189
71. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 1999; 100: 230-235
72. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM, Jr.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 1998; 279: 1615-1622
73. Ridker PM, Cannon C P, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E: C-reactive protein levels and outcomes after statin therapy. N Engl J Med, 2005; 352: 20-28
74. Laufs U, Marra D, Node K, Liao JK: 3-Hydroxy-3-meth-ylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem, 1999; 274: 21926-21931
75. Bourcier T, Libby P: HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arte-rioscler Thromb Vasc Biol, 2000; 20: 556-562
76. Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E: Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against ath-erothrombosis. Arterioscler Thromb Vasc Biol, 1997; 17: 265-272
77. Laufs U, La Fata V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation, 1998; 97: 1129-1135
78. Mason R P, Kubant R, Heeba G, Jacob RF, Day CA, Med-lin YS, Funovics P, Malinski T: Synergistic effect of amlo-dipine and atorvastatin in reversing LDL-induced endo-thelial dysfunction. Pharm Res, 2008; 25: 1798-1806
79. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn A P, Ganz P: The effect of cholesterol-lowering and antioxi-dant therapy on endothelium-dependent coronary vaso-motion. N Engl J Med, 1995; 332: 488-493
80. Kinlay S: Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-re-active protein: a meta-analysis. J Am Coll Cardiol, 2007; 49: 2003-2009
81. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK, Egashira K, Iguchi A: Cerivastatin, a hy-droxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation, 2001; 104: 376-379
82. Beckman JA, Liao JK, Hurley S, Garrett LA, Chui D, Mi-tra D, Creager MA: Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res, 2004; 95: 217-223